Absence of prognostic significance of p21(WAF1/CIP1) protein expression in non-small cell lung cancer

Acta Oncol. 2005;44(1):75-9. doi: 10.1080/02841860510007422.

Abstract

Prognostic value of p21WAF1/CIP1 expression in non-small-cell lung cancer patients (NSCLC) remains unclear. In this study the authors investigated the clinical significance of p21WAF1/CIP1 expression in a group of 117 NSCLC patients, who underwent curative pulmonary resection. Expression of p21WAF1/CIP1 protein was assessed immunohistochemically and samples showing>5% of positive tumor cells were considered positive. Seventy-six samples (65%) showed positive nuclear p21WAF1/CIP1 protein expression. There was no relationship between the expression of p21WAF1/CIP1 protein and major clinico-pathological factors, and neither there was an impact of p21WAF1/CIP1 protein expression on disease-free and overall survival. p21WAF1/CIP1 protein occurrence was not correlated with previously determined p53 protein expression and there was also no relationship between all possible p21WAF1/CIP1/p53 phenotypes and survival. In uni- and multivariate analysis only stage of disease was independent prognostic factors. These results suggest the lack of prognostic relevance of p21WAF1/CIP1 expression (analyzed separately or jointly with p53 protein) in surgically treated NSCLC patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Cyclin-Dependent Kinase Inhibitor p21
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality*
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Pneumonectomy / methods
  • Prognosis
  • Proportional Hazards Models
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Sensitivity and Specificity
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • CDKN1A protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p21